Affiliation:
1. First Affiliated Hospital of Fujian Medical University
Abstract
Abstract
Objective
This study aimed to determine whether a relationship exist between pre-therapy 25-hydroxyvitamin D levels and the remission/negative conversion rates of thyrotropin receptor antibody (TRAB) during treatment in patients with newly diagnosed Graves' disease (GD).
Methods
171 patients were included from the Endocrinology Department of the First Affiliated Hospital of Fujian Medical University in March 2013 to April 2016. Ninety-five patients of them were diagnosed at our hospital but transferred to local hospitals for treatment. Seventy-six patients were followed and treated at our hospital with a median follow-up time of 11.03 (range 6–27) months. Patients were divided into 3 groups according to baseline 25-hydroxyvitamin D levels; <20 ng/mL (31,43.05%), 20–29 ng /mL (20,27.78%), and ≥ 30 ng/mL (20,29.17%). The TRAB remission rate and negative conversion rate was assessed among each group.
Results
There was a higher TSH and lower TRAB titer in the 20–29 ng/mL group at initial diagnosis. Cox regression analysis suggested that 20–29 ng/mL group had significantly higher remission rates [RR; 95% CI: 7.505 (1.401–40.201), 8.975 (2.759–29.196),6.853(2.206–21.285), respectively] and negative conversion rates [RR; 95% CI: 7.835 (1.468–41.804),7.189(1.393–37.092), 8.122(1.621–40.688)] at the 6-, 12-, and 24-month follow-up, respectively .The level of 25-hydroxyvitamin D at the time of initial diagnosis was not associated with the re-normal of free Triiodothyronine(FT3), free thyroxineIndex(FT4) or TSH levels during the follow-up.
Conclusion
Newly diagnosed GD patients with appropriate baseline 25-hydroxyvitamin D levels (20–29 ng/mL) are beneficial for the reduction of TRAB during antithyroid therapy.
Publisher
Research Square Platform LLC
Reference29 articles.
1. The Mediation Role of Thyrotropin Receptor Antibody in the Relationship Between Age and Severity of Hyperthyroidism in Graves' Disease;Suzuki N;Thyroid: official journal of the American Thyroid Association,2022
2. Gut Microbiome Associated With Graves Disease and Graves Orbitopathy: The INDIGO Multicenter European Study;Biscarini F;J Clin Endocrinol Metab,2023
3. Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study;Okosieme OE;The lancet Diabetes & endocrinology,2019
4. Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis;Wiersinga WM;The lancet Diabetes & endocrinology,2023
5. Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease;Nedrebo BG;Eur J Endocrinol,2002